rs11212617 — ATM

Intronic variant near the ATM gene affecting metformin's activation of AMPK; the C allele confers improved glycemic response to metformin and links the DNA damage response pathway to longevity-relevant AMPK-mTOR signaling

See your personal result for ATM

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ATM rs11212617 — Where DNA Repair Meets Longevity Pharmacology

The ataxia telangiectasia mutated (ATM) gene encodes one of the master regulators of the cellular DNA damage response — a kinase that springs into action when double-strand DNA breaks are detected, coordinating cell cycle arrest, DNA repair, and, when damage is irreparable, programmed cell death. What makes ATM central to longevity biology is what it does downstream: ATM activates AMPK11 AMPK
AMP-activated protein kinase — the cell's master energy sensor, activated when ADP/AMP ratios rise, and the primary target of metformin's longevity effects, which in turn inhibits mTOR and triggers autophagy. This positions ATM not just as a DNA repair enzyme but as a node connecting genomic stability to the metabolic hallmarks of aging.

The rs11212617 variant sits in an intron within the ATM locus on chromosome 11q22, inside a 340 kb linkage disequilibrium block. The C allele is associated with enhanced metformin response, suggesting it may modify how efficiently ATM activates AMPK under metabolic stress — the same pathway that metformin engages when it inhibits mitochondrial complex I and raises the AMP:ATP ratio.

The Mechanism

Metformin's primary action is inhibition of mitochondrial complex I in the electron transport chain, raising the cellular AMP:ATP ratio and directly activating AMPK. But metformin also appears to engage the ATM-AMPK axis: experimental work using ATM inhibitor KU-55933 in rat hepatoma cells22 experimental work using ATM inhibitor KU-55933 in rat hepatoma cells
Zhou K et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics, 2011 showed attenuated AMPK phosphorylation in response to metformin when ATM was blocked. The mechanistic interpretation was complicated by a subsequent finding that KU-55933 also inhibits OCT1 (a metformin transporter), potentially reducing intracellular metformin rather than directly blocking an ATM-AMPK signal. Whether ATM acts directly on AMPK, indirectly through modulating DNA damage-sensing cascades that converge on AMPK, or primarily via effects on metformin transport remains an active question.

What is established is that activated ATM phosphorylates and stabilizes SIRT6, and that ATM activity also restrains mTORC1 via the AMPK-TSC2 pathway after DNA damage. Boosting ATM activity extended lifespan in mouse models of progeria33 Boosting ATM activity extended lifespan in mouse models of progeria
Qian M et al. Boosting ATM activity alleviates aging and extends lifespan in a mouse model of progeria. eLife, 2018, and ATM-deficient mice show accelerated metabolic dysfunction and premature aging — establishing the gene's role in organismal longevity beyond its classic function in cancer suppression.

The Evidence

The landmark GWAS by Zhou et al. 201144 The landmark GWAS by Zhou et al. 2011
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics discovered rs11212617 by scanning 1,024 Scottish type 2 diabetes patients on metformin. In the combined meta-analysis of 3,920 patients, the C allele reached genome-wide significance (P=2.9×10⁻⁹) for metformin treatment success (achieving HbA1c below 7%), with an odds ratio of 1.35 (95% CI 1.22–1.49). Each additional C allele correlated with 0.11% lower HbA1c on metformin treatment (P=6.6×10⁻⁷).

Van Leeuwen et al. 201255 Van Leeuwen et al. 2012
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia replicated the association across three new cohorts and declared rs11212617 the first robustly replicated common pharmacogenetic variant for metformin (combined five-cohort OR 1.25, P=7.8×10⁻⁶).

However, Florez et al. 201266 Florez et al. 2012
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care failed to confirm the association in 2,994 participants treated with metformin for diabetes prevention (HR 1.17, P=0.13). The authors note an important distinction: the DPP enrolled prediabetic individuals while the discovery GWAS enrolled established type 2 diabetics — the biological context of metformin's action may differ substantially between these populations. Multiple other studies in European, South Asian, and East Asian populations have found inconsistent replication, suggesting the association may be population-specific or context-dependent.

In an independent direction, Cuyàs et al. 201977 Cuyàs et al. 2019
METTEN trial — Frontiers in Oncology found that C allele carriers among HER2-positive breast cancer patients had a 7.94-fold higher probability of pathological complete response when treated with neoadjuvant metformin (p=0.011), while no association existed in the control arm — extending the variant's pharmacogenetic relevance to cancer treatment.

The mixed replication record is reflected in the moderate evidence level: the initial GWAS signal is robust within European type 2 diabetes cohorts, but context-dependence, population variation, and an unresolved molecular mechanism prevent elevation to strong.

Practical Actions

The core implication of rs11212617 is pharmacogenetic: C allele carriers — both AC heterozygotes and CC homozygotes — appear to show improved glycemic response to metformin in the context of established type 2 diabetes. For individuals with AA genotype who are prescribed metformin, awareness that this variant may confer reduced metformin efficacy is worth discussing with a clinician, particularly if glycemic targets are not met at standard doses.

Beyond pharmacogenetics, the ATM pathway connects to the same AMPK-mTOR axis that underlies caloric restriction and intermittent fasting biology. The TAME trial (Targeting Aging with Metformin)88 TAME trial (Targeting Aging with Metformin) is currently testing whether metformin can extend healthspan in non-diabetic older adults specifically through these longevity pathways. Individual rs11212617 genotype may ultimately predict differential benefit even in that prevention context.

Interactions

rs11212617 operates within the same AMPK-mTOR axis as rs2295080 (MTOR promoter variant). Individuals carrying both the ATM rs11212617 A allele (reduced ATM-AMPK coupling) and MTOR rs2295080 TT genotype (highest mTOR expression) would face a compound disadvantage: reduced capacity to activate AMPK through the ATM route combined with elevated constitutive mTOR activity. This biologically plausible interaction has not been formally tested in a published combined-genotype study. rs2802292 (FOXO3) is also a longevity pathway partner: FOXO3 activity is downstream of AMPK and upstream mTOR signaling, making all three variants part of the same regulatory circuit linking DNA damage response to cellular aging.

Drug Interactions

metformin reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard Metformin Responder Normal

Common genotype — standard metformin response without the C allele pharmacogenetic advantage

You have two copies of the A allele at rs11212617, the most common configuration in European populations (approximately 28% of individuals). This genotype does not carry the C allele that has been associated with enhanced metformin response in type 2 diabetes treatment in European GWAS and replication studies.

You are likely to respond to metformin at standard doses, but without the additional glycemic benefit that C allele carriers appear to derive in the context of established type 2 diabetes. If you are prescribed metformin and glycemic targets are not met at standard doses, this genotype is worth flagging to your clinician as one factor that may be relevant to dose optimization.

CC Enhanced Metformin Responder Beneficial

Two C alleles — strongest pharmacogenetic signal for metformin response in type 2 diabetes

The CC genotype's advantage appears to reflect more efficient ATM-AMPK pathway coupling in response to metformin, though the precise mechanism remains under investigation. The alternative possibility — that the variant modulates OCT1-mediated metformin transport into hepatocytes — has not been ruled out, and the two mechanisms are not mutually exclusive.

From a longevity perspective, the ATM gene's broader role is worth understanding. ATM phosphorylates SIRT6 at serine 112, protecting it from MDM2-mediated degradation and preserving metabolic homeostasis. In progeria mouse models, activating ATM extended lifespan, reduced DNA damage accumulation, and improved mitochondrial function — establishing ATM activity as causally relevant to aging biology. The rs11212617 C allele may represent a modest constitutive advantage in this ATM-SIRT6-metabolic axis that manifests most clearly when pharmacological ATM-AMPK activation (via metformin) is applied.

Note: The DPP study found no advantage for C carriers when metformin was used for diabetes prevention in prediabetic individuals, suggesting the pharmacogenetic effect may be specific to the established type 2 diabetes context rather than universal.

AC Partial Metformin Advantage Intermediate

One C allele — partial pharmacogenetic benefit for metformin response

The effect of rs11212617 follows a codominant pattern in the discovery GWAS, where each additional C allele provides additional protection. The combined GWAS+replication odds ratio of 1.35 applies to C allele carriers overall; the per-allele effect corresponds to approximately 0.11% lower HbA1c per C allele under metformin treatment (P=6.6×10⁻⁷).

From a longevity biology perspective, the ATM gene plays a role in SIRT6 stabilization and AMPK-mTOR axis regulation that extends well beyond metformin pharmacogenetics. ATM activity promotes genomic stability, suppresses mTORC1 after DNA damage, and coordinates the metabolic shifts that characterize the cellular response to stress — the same pathways that caloric restriction and intermittent fasting engage.